JP2019537576A - 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用 - Google Patents
神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用 Download PDFInfo
- Publication number
- JP2019537576A JP2019537576A JP2019522377A JP2019522377A JP2019537576A JP 2019537576 A JP2019537576 A JP 2019537576A JP 2019522377 A JP2019522377 A JP 2019522377A JP 2019522377 A JP2019522377 A JP 2019522377A JP 2019537576 A JP2019537576 A JP 2019537576A
- Authority
- JP
- Japan
- Prior art keywords
- aav
- tpp1
- particles
- mammal
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 114
- 108090000623 proteins and genes Proteins 0.000 title claims description 76
- 239000000203 mixture Substances 0.000 title description 18
- 238000012546 transfer Methods 0.000 title description 8
- 208000015122 neurodegenerative disease Diseases 0.000 title description 3
- 230000004770 neurodegeneration Effects 0.000 title description 2
- 239000002245 particle Substances 0.000 claims abstract description 211
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 89
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 88
- 229920001184 polypeptide Polymers 0.000 claims abstract description 86
- 241000124008 Mammalia Species 0.000 claims abstract description 75
- 230000014509 gene expression Effects 0.000 claims abstract description 75
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims abstract description 58
- 210000004556 brain Anatomy 0.000 claims abstract description 57
- 208000015439 Lysosomal storage disease Diseases 0.000 claims abstract description 30
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 claims description 187
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 claims description 163
- 150000007523 nucleic acids Chemical class 0.000 claims description 88
- 210000004027 cell Anatomy 0.000 claims description 75
- 102000039446 nucleic acids Human genes 0.000 claims description 71
- 108020004707 nucleic acids Proteins 0.000 claims description 71
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 230000000694 effects Effects 0.000 claims description 46
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 45
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 40
- 241000702421 Dependoparvovirus Species 0.000 claims description 38
- 210000000234 capsid Anatomy 0.000 claims description 38
- 239000003018 immunosuppressive agent Substances 0.000 claims description 34
- 206010044565 Tremor Diseases 0.000 claims description 29
- 101100261165 Homo sapiens TPP1 gene Proteins 0.000 claims description 28
- 101100426960 Homo sapiens TTPA gene Proteins 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 24
- 108090000565 Capsid Proteins Proteins 0.000 claims description 22
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 17
- 210000001638 cerebellum Anatomy 0.000 claims description 17
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 17
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 17
- 230000001861 immunosuppressant effect Effects 0.000 claims description 16
- 210000002442 prefrontal cortex Anatomy 0.000 claims description 16
- 239000003623 enhancer Substances 0.000 claims description 15
- 210000001577 neostriatum Anatomy 0.000 claims description 15
- 210000001103 thalamus Anatomy 0.000 claims description 15
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 13
- 108010036949 Cyclosporine Proteins 0.000 claims description 13
- 229960001265 ciclosporin Drugs 0.000 claims description 13
- 229930182912 cyclosporin Natural products 0.000 claims description 13
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical group COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 13
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 13
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 11
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 11
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 11
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 11
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 11
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 11
- 241000649045 Adeno-associated virus 10 Species 0.000 claims description 11
- 241000649046 Adeno-associated virus 11 Species 0.000 claims description 11
- 102000010911 Enzyme Precursors Human genes 0.000 claims description 11
- 108010062466 Enzyme Precursors Proteins 0.000 claims description 11
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 claims description 11
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 11
- 210000004962 mammalian cell Anatomy 0.000 claims description 11
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 10
- 229940014456 mycophenolate Drugs 0.000 claims description 10
- 229930105110 Cyclosporin A Natural products 0.000 claims description 8
- 210000003703 cisterna magna Anatomy 0.000 claims description 8
- 210000002216 heart Anatomy 0.000 claims description 8
- 210000000952 spleen Anatomy 0.000 claims description 8
- 241000649047 Adeno-associated virus 12 Species 0.000 claims description 7
- 238000007914 intraventricular administration Methods 0.000 claims description 7
- 230000002132 lysosomal effect Effects 0.000 claims description 7
- 210000002330 subarachnoid space Anatomy 0.000 claims description 6
- 102000007469 Actins Human genes 0.000 claims description 5
- 108010085238 Actins Proteins 0.000 claims description 5
- 241000283984 Rodentia Species 0.000 claims description 5
- 210000004289 cerebral ventricle Anatomy 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 210000005171 mammalian brain Anatomy 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 210000005241 right ventricle Anatomy 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 4
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims description 3
- 208000015178 Hurler syndrome Diseases 0.000 claims description 3
- 102000004157 Hydrolases Human genes 0.000 claims description 3
- 108090000604 Hydrolases Proteins 0.000 claims description 3
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
- 206010011777 Cystinosis Diseases 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 201000008892 GM1 Gangliosidosis Diseases 0.000 claims description 2
- 208000015872 Gaucher disease Diseases 0.000 claims description 2
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 2
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims description 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 2
- 208000028226 Krabbe disease Diseases 0.000 claims description 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims description 2
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 2
- 208000008955 Mucolipidoses Diseases 0.000 claims description 2
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 claims description 2
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 claims description 2
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims description 2
- 208000021811 Sandhoff disease Diseases 0.000 claims description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 2
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 2
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 2
- 210000005240 left ventricle Anatomy 0.000 claims description 2
- 201000007769 mucolipidosis Diseases 0.000 claims description 2
- 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 claims description 2
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 claims description 2
- 206010029864 nystagmus Diseases 0.000 claims description 2
- 230000011514 reflex Effects 0.000 claims description 2
- 210000004720 cerebrum Anatomy 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 230000003472 neutralizing effect Effects 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 244000101724 Apium graveolens Dulce Group Species 0.000 claims 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims 1
- 235000010591 Appio Nutrition 0.000 claims 1
- 208000035343 Infantile neurovisceral acid sphingomyelinase deficiency Diseases 0.000 claims 1
- 201000000794 Niemann-Pick disease type A Diseases 0.000 claims 1
- 208000007824 Type A Niemann-Pick Disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 230000009023 proprioceptive sensation Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 87
- 239000007924 injection Substances 0.000 abstract description 87
- 210000003169 central nervous system Anatomy 0.000 abstract description 15
- 210000000278 spinal cord Anatomy 0.000 abstract description 15
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 72
- 241000699670 Mus sp. Species 0.000 description 44
- 210000001519 tissue Anatomy 0.000 description 44
- 239000013598 vector Substances 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 30
- 102000053602 DNA Human genes 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 29
- 230000002093 peripheral effect Effects 0.000 description 26
- 102000040430 polynucleotide Human genes 0.000 description 25
- 108091033319 polynucleotide Proteins 0.000 description 25
- 239000002157 polynucleotide Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- 230000003612 virological effect Effects 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 19
- 241000700605 Viruses Species 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 239000013607 AAV vector Substances 0.000 description 14
- 108020004705 Codon Proteins 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 230000002255 enzymatic effect Effects 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 231100000673 dose–response relationship Toxicity 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- 241000701022 Cytomegalovirus Species 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 230000036961 partial effect Effects 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 239000013646 rAAV2 vector Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 229920002477 rna polymer Polymers 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000007619 statistical method Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 208000025014 late infantile neuronal ceroid lipofuscinosis Diseases 0.000 description 8
- 238000001422 normality test Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000013608 rAAV vector Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010015548 Euthanasia Diseases 0.000 description 5
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- -1 for example Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229960002725 isoflurane Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 230000004543 DNA replication Effects 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 108090000157 Metallothionein Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000003140 lateral ventricle Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 210000001767 medulla oblongata Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000010473 stable expression Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 101100207331 Arabidopsis thaliana TPPI gene Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101150100050 CLN2 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 101100261167 Mus musculus Tpp1 gene Proteins 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000701945 Parvoviridae Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 101150092324 TPP1 gene Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 210000003059 ependyma Anatomy 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000004324 time-proportional phase incrementation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- FVRLYIFIDKXFHU-UHFFFAOYSA-N 2-[2-(2-aminopropanoylamino)propanoylamino]-n-(4-methyl-2-oxochromen-7-yl)-3-phenylpropanamide Chemical compound C=1C=C2C(C)=CC(=O)OC2=CC=1NC(=O)C(NC(=O)C(C)NC(=O)C(N)C)CC1=CC=CC=C1 FVRLYIFIDKXFHU-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 1
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031873 Animal Disease Models Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 208000009642 Severe combined immunodeficiency due to adenosine deaminase deficiency Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108010005897 alanyl-alanyl-phenylalanyl-7-amino-4-methylcoumarin Proteins 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000011558 animal model by disease Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- 210000004055 fourth ventricle Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
[0130]文脈により、そうでないことが明確に指し示されない限りにおいて、本明細書で使用される、全ての数値又は範囲は、値の分数と、このような範囲内の整数と、このような範囲内の整数の分数とを含む。したがって、例示のために述べると、1〜10などの数値範囲に対する言及は、1、2、3、4、5、6、7、8、9、10のほか、1.1、1.2、1.3、1.4、1.5などを含む。したがって、1〜50の範囲に対する言及は、最大で50であり、これを含む、1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20などのほか、1.1、1.2、1.3、1.4、1.5など、2.1、2.2、2.3、2.4、2.5などを含む。
[0134]ヒトTPP1配列
ヒトTPP1タンパク質配列(配列番号1):
MGLQACLLGLFALILSGKCSYSPEPDQRRTLPPGWVSLGRADPEEELSLTFALRQQNVERLSELVQAVSDPSSPQYGKYLTLENVADLVRPSPLTLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHHYVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHHFPPTSSLRQRPEPQVTGTVGLHLGVTPSVIRKRYNLTSQDVGSGTSNNSQACAQFLEQYFHDSDLAQFMRLFGGNFAHQASVARVVGQQGRGRAGIEASLDVQYLMSAGANISTWVYSSPGRHEGQEPFLQWLMLLSNESALPHVHTVSYGDDEDSLSSAYIQRVNTELMKAAARGLTLLFASGDSGAGCWSVSGRHQFRPTFPASSPYVTTVGGTSFQEPFLITNEIVDYISGGGFSNVFPRPSYQEEAVTKFLSSSPHLPPSSYFNASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLINEHRILSGRPPLGFLNPRLYQQHGAGLFDYTRGCHESCLDEEVEGQGFCSGPGWDPVTGWGTPNFPALLKTLLNP
ヒトTPP1核酸配列(配列番号2):
CAGプロモーター配列(配列番号3):
その他の特徴 1 1672 /注=CAGプロモーター
調節的 22 327 /注=CMVエンハンサー
プロモーター 328 605 /注=ニワトリベータ−アクチンプロモーター
イントロン 607 1624 /注=キメライントロン、/注=ニワトリベータ−アクチンに由来するイントロンと、ウサギベータ−グロビンに由来するイントロンとの間のキメラ
調節的 1528 1672 /注=予測される転写因子部位
調節的 1575 1672 /注=アイオワ予測による転写因子結合性部位
ATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCGGGGAGTCGCTGCGACGCTGCCTTCGCCCCGTGCCCCGCTCCGCCGCCGCCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCGCTTGGTTTAATGACGGCTTGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTGAGGGGCTCCGGGAGGGCCCTTTGTGCGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTGTGTGTGCGTGGGGAGCGCCGCGTGCGGCTCCGCGCTGCCCGGCGGCTGTGAGCGCTGCGGGCGCGGCGCGGGGCTTTGTGCGCTCCGCAGTGTGCGCGAGGGGAGCGCGGCCGGGGGCGGTGCCCCGCGGTGCGGGGGGGGCTGCGAGGGGAACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGTGAGCAGGGGGTGTGGGCGCGTCGGTCGGGCTGCAACCCCCCCTGCACCCCCCTCCCCGAGTTGCTGAGCACGGCCCGGCTTCGGGTGCGGGGCTCCGTACGGGGCGTGGCGCGGGGCTCGCCGTGCCGGGCGGGGGGTGGCGGCAGGTGGGGGTGCCGGGCGGGGCGGGGCCGCCTCGGGCCGGGGAGGGCTCGGGGGAGGGGCGCGGCGGCCCCCGGAGCGCCGGCGGCTGTCGAGGCGCGGCGAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCGAGAGGGCGCAGGGACTTCCTTTGTCCCAAATCTGTGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGCGGGGCGAAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCGCCGCGCCGCCGTCCCCTTCTCCCTCTCCAGCCTCGGGGCTGTCCGCGGGGGGACGGCTGCCTTCGGGGGGGACGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCTGCTAACCATGTTCATGCCTTCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTATTGTGCTGTCTCATCATTTTGGCAAA
[0136]組織試料中のTPPI活性:TPP1活性は、既に記載された改変法(Sohar,I.ら、2000、Clin Chem、46:1005〜8)を使用してアッセイした。略述すると、試料を、実験室用ホモジナイザー(P200;Pro Scientific、Oxford、CT)により、200μlの氷冷ホモジナイゼーション緩衝液(コンプリートプロテアーゼインヒビターカクテル(Complete Protease Inhibitor Cocktail)(Roche、Mannheim、Germany)を伴う、通常の生理食塩液において、0.1%のトリトンX−100(Triton X−100))においてホモジナイズした。不溶性物質は、21×103rcf、4℃で、15分間にわたる遠心分離により、ホモジネートから除去し、上清中のタンパク質含量は、DCプロテインアッセイ(DC Protein Assay)(Biorad、Hercules、CA)により定量化した。タンパク質(10μl)を、酵素基質と共に、100mMのクエン酸ナトリウム緩衝液、150mMのNaCl、及び0.1%のトリトンX−100(pH4.0)による90μlを含有する、96ウェルブラックウォールプレートのウェルへと添加した(クエン酸ナトリウム緩衝液中の250μmol/lのAla−Ala−Phe7−アミド−4−メチルクマリン、ph4.0)。プレートは、37℃で、励起波長を355±9nmとし、発光波長を460±15nmとし、スペクトラマックスM5(SpectraMax M5)マイクロプレートリーダー(Molecular Devices、Sunnyvale、CA)を使用して定量化した。精製された組換えヒトTPP1(P.Lobel、State University of New Jersey、NJからの恵与)を、標準物質として使用した。
DNA 1mg当たりのAAV4ゲノムコピー数(vg)=2×(1ml当たりのAAV4コピー数)試料/(1ml当たりのmg単位のDNA)試料
により計算した。
[0144]TPP1を発現しない、CLN2ノックアウト(CLN−/−)マウスモデルを使用して、用量反応研究及び安定性研究を実施した。用量反応研究は、注射時において、5〜8週齢の間のマウス30例(雌16例、雄14例)を組み入れた。安定性研究は、注射時において、6〜8週齢の間のマウス14例(雌7例、雄7例)を組み入れた。
[0153]投与研究の概要。ヒトTPP1(hTPP1)酵素活性アッセイを、CSF試料、脳試料、及び末梢試料に対して行った。CSFを、各処置群内の、全ての動物からプールした。結果は、内因性のマウスTPP1レベル(タンパク質1mg当たり0.34ピコモル;図3)と比べて、明確な用量反応を示す。組換えTPP1レベルは、1×1010、5×1010、及び1×1011vgの用量それぞれについて、タンパク質1mg当たり0.83、12.66、及び63.70ピコモルのTPP1であった。
結論
[0159]投与研究。CSF中の組換えTPP1レベルは、AAV4CAGhTPP1注射の5週間後における用量反応パターンを提示した。
死後解析
[0165]投与研究。全ての処置群は、CSF中のhTPP1プロ酵素レベルを、CLN2+/−動物における内因性レベルより高レベルで発現した(図1)。3つの処置群について、有意な線形相関が見られた(r2=0.91)ことから、強い用量反応が指し示される。高用量のAAV4CAGhTPP1(1×1011vg)を注射されたCLN2−/−マウスは、プロ酵素発現を、約187倍に増大させた。中用量(5×1010vg)は、内因性レベルと比べて、約37倍に増大させた。最も重要なことは、低用量(1×1010vg)もまた、内因性レベルより高度な、TPP1プロ酵素レベル(約2.4倍の増大)を達成したことである。
[0169]投与研究。ウイルスの生体内分布について解析するように、AAV4CAGhTPP1特異的プローブを使用して、Q−PCRを実施した。高濃度のAAV4ウイルスゲノムが、上衣細胞を含有する実質パンチに局在化した。動物間で、ばらつきが見出されたが、小脳及び延髄において、高レベルのウイルス粒子を発現する傾向が見られた。いずれの領域も、注射点から遠位に位置する第IV脳室に付随する。これらの結果は、急速なCSFの流動により、ウイルスゲノム(vg)が、注射部位から、第IV脳室へと輸送されること(図3)を指し示す。
[0171]投与研究。12週齢の非処置CLN2−/−マウスは、振戦活動の増強を呈した。週齢をマッチさせたCLN2−/−マウスであって、AAV4CAGhTPP1 1×1010又は5×1010個を施されたマウスは、周波数を14〜48Hzの間とする振戦振幅を、有意に減少させた(図4)。高用量群の振戦振幅には、対照CLN2+/−マウスと比較して、差違が見られなかったので、高(5×1010)用量のAAV4CAGhTPP1は、疾患表現型を、完全に防止した。
[0172]アカゲザルにおいて、研究を実施して、hTPP1を発現させるAAVベクターの、脳室内単回投与後の時間経過にわたり、CSF中のTPP1の発現プロファイルについて評価した。このために、3×1013vgのAAV2.CAGhTPP1を含有する4mLを、3例のアカゲザルの側脳室の右後角へと、片側注入した。CSF試料を、注射の前(0日目)、及び7日ごとに回収した。動物は、注射の6週間後に屠殺した。
[0001]本出願は、2016年11月4日に出願された、米国特許仮出願第64/418,033号に対する優先権を主張する。全ての本文、表、配列表、及び図面を含む、前出の出願の内容の全体は、参照により本明細書に組み込まれる。
Claims (67)
- リソソーム蓄積症(LSD)を有する哺乳動物を処置する方法であって、
哺乳動物の脳又は脊柱へ、複数のAAV粒子を投与するステップ
を含み、前記AAV粒子が、
(i)AAVカプシドタンパク質と;
(ii)AAV末端逆位配列(ITR)の対の間に挿入された核酸であり、リソソームヒドロラーゼ活性を有するポリペプチドをコードする核酸と;
(iii)前記核酸の発現を駆動する発現制御エレメントと
を含み、前記AAV粒子が、前記哺乳動物の細胞に形質導入し、前記ポリペプチドの発現をもたらすことが可能である方法。 - 前記ポリペプチドが、トリペプチジルペプチダーゼ1(TPP1)活性を有する、請求項1に記載の方法。
- 前記ポリペプチドが、TPP1、そのプロ酵素、又は酵素的に活性なその変異体を含む、請求項1に記載の方法。
- 前記AAV ITRのうちの1つ又は複数が、1つ又は複数のAAV2 ITRを含む、請求項1に記載の方法。
- 前記核酸が、哺乳動物TPP1をコードする、請求項1に記載の方法。
- 前記核酸が、ヒトTPP1をコードする、請求項1に記載の方法。
- 前記核酸が、TPP1活性を伴い、配列番号1として明示されたヒトTPP1に対して、80%以上の同一性を有するタンパク質をコードする、請求項1に記載の方法。
- 前記発現制御エレメントが、CMVエンハンサーを含む、請求項1〜7のいずれか一項に記載の方法。
- 前記発現制御エレメントが、ベータアクチンプロモーターを含む、請求項1〜7のいずれか一項に記載の方法。
- 前記発現制御エレメントが、ニワトリベータアクチンプロモーターを含む、請求項1〜7のいずれか一項に記載の方法。
- 前記発現制御エレメントが、CMVエンハンサー及びニワトリベータアクチンプロモーターを含む、請求項1〜7のいずれか一項に記載の方法。
- 前記発現制御エレメントが、配列番号3に明示されたCMVエンハンサーに対して、80%以上の同一性を有する配列、及び/又は配列番号3に明示されたニワトリベータアクチンプロモーターに対して、80%以上の同一性を有する配列を含む、請求項1〜7のいずれか一項に記載の方法。
- 前記発現制御エレメントが、配列番号3に対して、80%以上の同一性を有する配列を含む、請求項1〜7のいずれか一項に記載の方法。
- 前記発現制御エレメントが、配列番号3を含む、請求項1〜7のいずれか一項に記載の方法。
- カプシド配列が、AAV1、AAV2、AAV3、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10、AAV11、Rh10、Rh74、又はAAV−2i8のVP1配列、VP2配列、及び/又はVP3配列に対して、70%以上の同一性を有するVP1カプシド配列、VP2カプシド配列、及び/又はVP3カプシド配列を含む、請求項1〜14のいずれか一項に記載の方法。
- カプシド配列が、AAV2に対して、80%以上の同一性を有するVP1カプシド配列を含み、この場合、カプシド配列は、444、500、及び/又は730位におけるチロシンが、チロシンではないアミノ酸で置換されている、請求項1〜14のいずれか一項に記載の方法。
- カプシド配列が、AAV2に対して、90%以上の同一性を有するVP1カプシド配列を含み、この場合、カプシド配列は、444、500、及び/又は730位におけるチロシンが、フェニルアラニンで置換されている、請求項1〜14のいずれか一項に記載の方法。
- カプシド配列が、444、500、及び/又は730位におけるチロシンが、フェニルアラニンで置換されたAAV2 VP1カプシド配列を含む、請求項1〜14のいずれか一項に記載の方法。
- カプシド配列が、AAV1、AAV2、AAV3、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10、AAV11、Rh10、Rh74、又はAAV−2i8のAAV血清型のうちのいずれかから選択されるVP1カプシド配列、VP2カプシド配列、又はVP3カプシド配列を含む、請求項1〜14のいずれか一項に記載の方法。
- 前記複数のAAV粒子を、前記哺乳動物の脳へと投与するステップを含む、請求項1〜19のいずれか一項に記載の方法。
- 前記複数のAAV粒子を、前記哺乳動物の大槽、脳室内腔、脳室、くも膜下腔、髄内腔、及び/又は上衣へと投与するステップを含む、請求項1〜19のいずれか一項に記載の方法。
- 前記複数のAAV粒子を、前記哺乳動物の脳脊髄液(CSF)へと投与するステップを含む、請求項1〜19のいずれか一項に記載の方法。
- 前記複数のAAV粒子を、脳室系へと投与するステップを含む、請求項1〜19のいずれか一項に記載の方法。
- 前記複数のAAV粒子を、吻側側脳室へと投与するステップを含む、請求項1〜19のいずれか一項に記載の方法。
- 前記複数のAAV粒子を、尾側側脳室へと投与するステップを含む、請求項1〜19のいずれか一項に記載の方法。
- 前記複数のAAV粒子を、右側脳室及び/又は左側脳室へと投与するステップを含む、請求項1〜19のいずれか一項に記載の方法。
- 前記複数のAAV粒子を、右吻側側脳室及び/又は左吻側側脳室へと投与するステップを含む、請求項1〜19のいずれか一項に記載の方法。
- 前記複数のAAV粒子を、右尾側側脳室及び/又は左尾側側脳室へと投与するステップを含む、請求項1〜19のいずれか一項に記載の方法。
- 前記AAV粒子が、前記哺乳動物の上衣細胞に接触する、請求項1〜28のいずれか一項に記載の方法。
- 前記哺乳動物へと、第1の免疫抑制剤を投与するステップをさらに含む、請求項1〜29のいずれか一項に記載の方法。
- 前記哺乳動物へと、第2の免疫抑制剤を投与するステップをさらに含む、請求項30に記載の方法。
- 前記第1の免疫抑制剤及び前記第2の免疫抑制剤のうちの少なくとも1つを、前記AAV粒子の投与の前に、前記哺乳動物へと投与する、請求項30又は31に記載の方法。
- 前記第1の免疫抑制剤を、前記AAV粒子の投与の前に投与し、前記第2の免疫抑制剤を、前記AAV粒子の投与の前に、投与と同時に、又は投与の後で投与する、請求項30又は31に記載の方法。
- 前記第1の免疫抑制剤が、シクロスポリンを含む、請求項30〜33のいずれか一項に記載の方法。
- 前記シクロスポリンを、1日2回、約5〜20mg/kgの投与量で、少なくとも3カ月間にわたり投与する、請求項34に記載の方法。
- 投与される前記シクロスポリンの用量を、前記AAV粒子の投与の1〜2カ月後に低減する、請求項34に記載の方法。
- 前記第2の免疫抑制剤が、ミコフェノレート又はその誘導体を含む、請求項30〜36のいずれか一項に記載の方法。
- 前記ミコフェノレートの誘導体が、ミコフェノール酸モフェチル(MMF)である、請求項37に記載の方法。
- (i)前記第1の免疫抑制剤を、前記AAV粒子の投与の、少なくとも約2週間前に投与し、(ii)前記第2の免疫抑制剤を、前記AAV粒子の投与の約2週間前に、又は投与後60日以内に投与する、請求項30〜38のいずれか一項に記載の方法。
- 前記ミコフェノレート又はその誘導体を、1日約5〜20mg/kgの投与量で投与する、請求項37〜39のいずれか一項に記載の方法。
- 前記AAV粒子を、1kg当たり約1×108〜約1×1015vgの用量で投与する、請求項1〜40のいずれか一項に記載の方法。
- 前記哺乳動物の脳脊髄液(CSF)を構成する細胞に、前記AAV粒子により形質導入する、請求項1〜41のいずれか一項に記載の方法。
- 前記AAV粒子が、前記哺乳動物の上衣細胞に形質導入する、請求項1〜42のいずれか一項に記載の方法。
- 前記AAV粒子を形質導入された細胞が、前記ポリペプチドを発現し前記哺乳動物のCSFへと分泌する、請求項1〜43のいずれか一項に記載の方法。
- 前記哺乳動物の脳脊髄液中のトリペプチジルペプチダーゼ1(TPP1)活性が、任意選択で、350日間を超える日数にわたり、タンパク質1mg当たり少なくとも5ピコモルのTPP1のレベルで検出可能である、請求項2〜44のいずれか一項に記載の方法。
- 前記哺乳動物が、非齧歯類哺乳動物である、請求項1〜45のいずれか一項に記載の方法。
- 前記非齧歯類哺乳動物が、霊長類動物である、請求項46に記載の方法。
- 前記非齧歯類哺乳動物が、ヒトである、請求項46に記載の方法。
- 前記ヒトが、小児である、請求項48に記載の方法。
- 前記小児が、約1〜約4歳である、請求項49に記載の方法。
- 前記LSDが、乳児神経セロイドリポフスチン症若しくは後期乳児神経セロイドリポフスチン症(LINCL)、神経障害性ゴーシェ病、若年性バッテン病、ファブリー病、MLD、A型サンフィリッポ病、ハンター病、クラッベ病、モルキオ病、ポンペ病、C型ニーマン−ピック病、テイ−サックス病、ハーラー病(MPS−I H)、B型サンフィリッポ病、マロトー−ラミー病、A型ニーマン−ピック病、シスチン症、ハーラー−シャイエ病(MPS−I H/S)、スライ症候群(MPS VII)、シャイエ病(MPS−I S)、乳児バッテン病、GM1ガングリオシドーシス、II/III型ムコ脂質症、又はサンドホフ病である、請求項1〜50のいずれか一項に記載の方法。
- 前記AAV粒子の投与が、前記AAV粒子の注射を含む、請求項1〜51のいずれか一項に記載の方法。
- 前記LSDと関連する症状の発症を、5〜10、10〜25、25〜50、又は50〜100日間遅延させる、請求項1〜52のいずれか一項に記載の方法。
- 前記症状が、固有感覚反応、眼振、威嚇瞬目反応、瞳孔対光反射、小脳性運動失調、及び企図振戦からなる群から選択される、請求項53に記載の方法。
- 前記LSDと関連する、認知機能の測定可能な喪失を、5〜10、10〜25、25〜50、又は50〜100日間遅延させる、請求項1〜54のいずれか一項に記載の方法。
- 前記LSDを有する哺乳動物の寿命を、5〜10、10〜25、25〜50、又は50〜100日間延長する、請求項1〜55のいずれか一項に記載の方法。
- 中和抗体が、前記AAV粒子の投与後、少なくとも30、60、90、又は120日間以上の日数にわたり、前記哺乳動物のCSFにおいて検出されない、請求項1〜56のいずれか一項に記載の方法。
- 中和抗体が、前記AAV粒子の前記投与後、少なくとも250日間にわたり、前記哺乳動物のCSFにおいて検出されない、請求項1〜57のいずれか一項に記載の方法。
- 前記ポリペプチドを、前記哺乳動物の脾臓又は心臓において発現させる、請求項1〜58のいずれか一項に記載の方法。
- 前記ポリペプチドを、前記哺乳動物の線条体、視床、髄質、小脳、大脳、後頭皮質、又は前頭前皮質において発現させる、請求項1〜59のいずれか一項に記載の方法。
- 前記発現制御エレメントが、前記哺乳動物の線条体、視床、髄質、小脳、大脳、後頭皮質、又は前頭前皮質のうちの1つ又は複数において、CMVプロモーターよりも高い、前記核酸又はポリペプチドの発現をもたらす、請求項1〜60のいずれか一項に記載の方法。
- 前記発現制御エレメントが、前記哺乳動物の線条体、視床、髄質、小脳、大脳、後頭皮質、又は前頭前皮質のうちの1つ又は複数において、CMVプロモーターよりも約1〜4倍高い、前記核酸又はポリペプチドの発現をもたらす、請求項1〜61のいずれか一項に記載の方法。
- 前記発現制御エレメントが、前記哺乳動物の線条体、視床、髄質、小脳、大脳、後頭皮質、又は前頭前皮質のうちの1つ又は複数において、CMVプロモーターよりも約1〜2倍高い、前記核酸又はポリペプチドの発現をもたらす、請求項1〜62のいずれか一項に記載の方法。
- 前記AAV粒子が、AAV1、AAV2、AAV3、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10、AAV11、AAV12、AAV−rh74、AAV−rh10、及びAAV−2i8の粒子からなる群から選択される、請求項1〜63のいずれか一項に記載の方法。
- 前記ITRのうちの1つ又は複数が、AAV1、AAV2、AAV3、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10、AAV11、AAV12、AAV−rh74、AAV−rh10、及びAAV−2i8のITRからなる群から選択される、請求項1〜64のいずれか一項に記載の方法。
- カプシド配列が、AAV1、AAV2、AAV3、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10、AAV11、Rh10、Rh74、又はAAV−2i8のVP1配列、VP2配列、及び/又はVP3配列に対して、90%以上の同一性を有するVP1カプシド配列、VP2カプシド配列、及び/又はVP3カプシド配列を含む、請求項1〜65のいずれか一項に記載の方法。
- カプシド配列が、AAV1、AAV2、AAV3、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10、AAV11、Rh10、Rh74、又はAAV−2i8のAAV血清型のうちのいずれかから選択されるVP1カプシド配列、VP2カプシド配列、又はVP3カプシド配列を含む、請求項1〜66のいずれか一項に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022169285A JP2023002721A (ja) | 2016-11-04 | 2022-10-21 | 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662418033P | 2016-11-04 | 2016-11-04 | |
US62/418,033 | 2016-11-04 | ||
PCT/US2017/059986 WO2018085688A1 (en) | 2016-11-04 | 2017-11-03 | Gene transfer compositions, methods and uses for treating neurodegenerative diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022169285A Division JP2023002721A (ja) | 2016-11-04 | 2022-10-21 | 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019537576A true JP2019537576A (ja) | 2019-12-26 |
JP2019537576A5 JP2019537576A5 (ja) | 2020-12-03 |
Family
ID=62075988
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019522377A Pending JP2019537576A (ja) | 2016-11-04 | 2017-11-03 | 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用 |
JP2022169285A Pending JP2023002721A (ja) | 2016-11-04 | 2022-10-21 | 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022169285A Pending JP2023002721A (ja) | 2016-11-04 | 2022-10-21 | 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20190269797A1 (ja) |
EP (1) | EP3534892A4 (ja) |
JP (2) | JP2019537576A (ja) |
CN (1) | CN110198712A (ja) |
AU (1) | AU2017355502B2 (ja) |
BR (1) | BR112019009074A2 (ja) |
CA (1) | CA3041548A1 (ja) |
MX (1) | MX2019005266A (ja) |
WO (1) | WO2018085688A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9818239B2 (en) | 2015-08-20 | 2017-11-14 | Zendrive, Inc. | Method for smartphone-based accident detection |
EP3635009A1 (en) | 2017-06-07 | 2020-04-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
WO2019079807A1 (en) | 2017-10-20 | 2019-04-25 | Zendrive, Inc. | METHOD AND SYSTEM FOR VEHICULAR COMMUNICATIONS |
AU2019346447A1 (en) | 2018-09-26 | 2021-04-29 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
SG11202104295UA (en) * | 2018-11-14 | 2021-06-29 | Regenxbio Inc | Gene therapy for neuronal ceroid lipofuscinoses |
US20220184188A1 (en) * | 2019-02-01 | 2022-06-16 | Spark Therapeutics, Inc. | Aav vector treatment methods for late infantile neuronal ceroid lipofuscinosis type 2 |
EP4042297A4 (en) | 2019-12-03 | 2023-11-22 | Zendrive, Inc. | METHOD AND SYSTEM FOR DETERMINING THE RISK OF A ROUTE |
CN115244181A (zh) * | 2020-03-11 | 2022-10-25 | 上海信致医药科技有限公司 | 阿司匹林化合物在增加核酸表达中的新型用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005120581A2 (en) * | 2004-06-07 | 2005-12-22 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
WO2015077473A1 (en) * | 2013-11-20 | 2015-05-28 | University Of Iowa Research Foundation | Methods and compositions for treating amyloid deposits |
US20150151007A1 (en) * | 2007-06-06 | 2015-06-04 | Genzyme Corporation | Gene therapy for lysosomal storage diseases |
JP2016530246A (ja) * | 2013-07-26 | 2016-09-29 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 脳疾患を処置するための方法および組成物 |
WO2017070678A1 (en) * | 2015-10-23 | 2017-04-27 | University Of Iowa Research Foundation | Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection |
JP2020519292A (ja) * | 2017-05-11 | 2020-07-02 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 神経セロイドリポフスチン症のための遺伝子療法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070003518A1 (en) * | 2002-04-19 | 2007-01-04 | Atkinson Mark A | Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases |
CA2554198A1 (en) * | 2004-01-22 | 2005-08-04 | Dnavec Research Inc. | Process for producing virus vector |
AR059371A1 (es) * | 2006-02-08 | 2008-03-26 | Genzyme Corp | Terapia genica para la enfermedad de niemann-pick tipo a |
US9849195B2 (en) * | 2011-03-31 | 2017-12-26 | University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
KR102380265B1 (ko) * | 2013-07-22 | 2022-03-29 | 더 칠드런스 호스피탈 오브 필라델피아 | 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 |
WO2015060722A1 (en) * | 2013-10-24 | 2015-04-30 | Uniqure Ip B.V. | Aav-5 pseudotyped vector for gene therapy for neurological diseases |
-
2017
- 2017-11-03 WO PCT/US2017/059986 patent/WO2018085688A1/en unknown
- 2017-11-03 JP JP2019522377A patent/JP2019537576A/ja active Pending
- 2017-11-03 US US16/344,298 patent/US20190269797A1/en active Pending
- 2017-11-03 EP EP17867272.1A patent/EP3534892A4/en active Pending
- 2017-11-03 MX MX2019005266A patent/MX2019005266A/es unknown
- 2017-11-03 CA CA3041548A patent/CA3041548A1/en active Pending
- 2017-11-03 CN CN201780067919.4A patent/CN110198712A/zh active Pending
- 2017-11-03 BR BR112019009074A patent/BR112019009074A2/pt active Search and Examination
- 2017-11-03 AU AU2017355502A patent/AU2017355502B2/en active Active
-
2022
- 2022-10-21 JP JP2022169285A patent/JP2023002721A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005120581A2 (en) * | 2004-06-07 | 2005-12-22 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
US20150151007A1 (en) * | 2007-06-06 | 2015-06-04 | Genzyme Corporation | Gene therapy for lysosomal storage diseases |
JP2016530246A (ja) * | 2013-07-26 | 2016-09-29 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 脳疾患を処置するための方法および組成物 |
WO2015077473A1 (en) * | 2013-11-20 | 2015-05-28 | University Of Iowa Research Foundation | Methods and compositions for treating amyloid deposits |
WO2017070678A1 (en) * | 2015-10-23 | 2017-04-27 | University Of Iowa Research Foundation | Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection |
JP2020519292A (ja) * | 2017-05-11 | 2020-07-02 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 神経セロイドリポフスチン症のための遺伝子療法 |
Non-Patent Citations (3)
Title |
---|
GENE THERAPY, vol. 14, JPN6019029404, 2007, pages 1249 - 1260, ISSN: 0004803584 * |
HUMAN GENE THERAPY, 2004, VOL.15, NO.11, PP.1131-1154, JPN6021038168, ISSN: 0004803583 * |
HUMAN GENE THERAPY, vol. 23, JPN6019029406, 2012, pages 202 - 209, ISSN: 0004803585 * |
Also Published As
Publication number | Publication date |
---|---|
RU2019117062A (ru) | 2020-12-04 |
US20190269797A1 (en) | 2019-09-05 |
JP2023002721A (ja) | 2023-01-10 |
WO2018085688A1 (en) | 2018-05-11 |
MX2019005266A (es) | 2019-09-27 |
BR112019009074A2 (pt) | 2019-07-16 |
AU2017355502A1 (en) | 2019-05-16 |
CN110198712A (zh) | 2019-09-03 |
RU2019117062A3 (ja) | 2021-03-11 |
AU2017355502B2 (en) | 2023-08-31 |
EP3534892A4 (en) | 2020-05-27 |
CA3041548A1 (en) | 2018-05-11 |
EP3534892A1 (en) | 2019-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3364970B1 (en) | Gene therapy for use in treating lysosomal storage disease | |
JP2022101648A (ja) | 一本鎖アデノ随伴ウイルス9または自己相補型アデノ随伴ウイルス9の脳脊髄液への注射 | |
JP2023002721A (ja) | 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用 | |
JP7436089B2 (ja) | 前頭側頭型認知症の治療 | |
US20210324354A1 (en) | Sulfamidase (sgsh) variants, vectors, compositions and methods and uses for treating mucopolysaccharidosis type iiia (mps iiia) | |
US20200360491A1 (en) | Treatment of lysosomal storage disease in the eye through administration of aavs expressing tpp1 | |
RU2805606C2 (ru) | Композиции, способы и применения переноса генов для лечения нейродегенеративных заболеваний | |
JP7507808B2 (ja) | 前頭側頭型認知症の治療 | |
US20230210941A1 (en) | Compositions useful in treatment of krabbe disease | |
JP2024084797A (ja) | 一本鎖アデノ随伴ウイルス9または自己相補型アデノ随伴ウイルス9の脳脊髄液への注射 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201022 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201022 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211005 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220330 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220621 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221020 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221021 |
|
C609 | Written withdrawal of request for trial/appeal |
Free format text: JAPANESE INTERMEDIATE CODE: C609 Effective date: 20221021 |
|
C116 | Written invitation by the chief administrative judge to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C116 Effective date: 20221129 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20221129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221208 |